The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based …

The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …

The immunogenicity of malignant cells has recently been acknowledged as a critical
determinant of efficacy in cancer therapy. Thus, besides developing direct …

When cells undergo necrotic cell death in either physiological or pathophysiological settings
in vivo, they release highly immunogenic intracellular molecules and organelles into the …

Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited
range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent …

The emerging role of the cancer cell-immune cell interface in shaping tumorigenesis/
anticancer immunotherapy has increased the need to identify prognostic biomarkers …

Photodynamic therapy (PDT) is an anticancer strategy utilizing light-mediated activation of a
photosensitizer (PS) which has accumulated in tumor and/or surrounding vasculature. Upon …

Metastatic colorectal cancer is the fourth most common cause of cancer death. Current
options in palliation such as hyperthermic intraperitoneal chemotherapy (HIPEC) present …

The ruthenium complex sodium trans-[tetrachloridobis (1 H-indazole) ruthenate
(iii)](KP1339/IT-139) showed preclinical activity in a variety of in vivo tumor models including …